{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:04:43Z","timestamp":1790305483311,"version":"4.1.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002383","name":"King Saud University","doi-asserted-by":"publisher","award":["ORF-2025-1049"],"award-info":[{"award-number":["ORF-2025-1049"]}],"id":[{"id":"10.13039\/501100002383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bioorg.2025.109162","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:58:16Z","timestamp":1761591496000},"page":"109162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Exploiting COX-2 engagement for amplifying anticancer potential of Quinazoline-triazole conjugates with superior EGFR\/VEGFR-2 inhibition"],"prefix":"10.1016","volume":"166","author":[{"given":"Marwa I.","family":"Serag","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Hamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman E.","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed R.","family":"Elnagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed M.","family":"Tawfik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel S.","family":"El-Azab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Brogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim A.","family":"Al-Suwaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hefnawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa A.-M.","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2025.109162_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bioorg.2025.109162_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2024.102716","article-title":"Updated cancer burden in oldest old: a population-based study using 2022 Globocan estimates","volume":"95","author":"Shah","year":"2025","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.bioorg.2025.109162_bb0015","series-title":"An introduction to fundamentals of cancer biology, Optical Polarimetric Modalities for Biomedical Research, Springer","first-page":"307","author":"Sriharikrishnaa","year":"2023"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109162_bb0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/ajio.ajio_3_25","article-title":"Advancing anticancer drug development: overcoming challenges and exploring new therapeutic strategies","volume":"2","author":"Sharma","year":"2025","journal-title":"Ayush Journal of Integrative Oncology"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109162_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01668-1","article-title":"Multifunctional nanoparticle-mediated combining therapy for human diseases","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109162_bb0030","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13065-022-00893-z","article-title":"Synthesis, biological evaluation, and computational studies of some novel quinazoline derivatives as anticancer agents","volume":"16","author":"Emami","year":"2022","journal-title":"BMC chemistry"},{"issue":"2","key":"10.1016\/j.bioorg.2025.109162_bb0035","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/cancers16020461","article-title":"Targeted therapeutic strategies for the treatment of cancer","volume":"16","author":"Victoir","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109162_bb0040","doi-asserted-by":"crossref","first-page":"2281262","DOI":"10.1080\/14756366.2023.2281262","article-title":"New pyrazolyl-thiazolidinone\/thiazole derivatives as celecoxib\/dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory\/anti-proliferative activities, apoptosis, molecular modelling and ADME studies","volume":"38","author":"Fadaly","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109162_bb0045","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1038\/modpathol.3801018","article-title":"Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond","volume":"21","author":"Ladanyi","year":"2008","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109162_bb0050","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/med.20070","article-title":"Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development","volume":"26","author":"Kamath","year":"2006","journal-title":"Med. Res. Rev."},{"issue":"7605","key":"10.1016\/j.bioorg.2025.109162_bb0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR (T790M) and EGFR (C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bioorg.2025.109162_bb0060","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1124\/jpet.112.197756","article-title":"Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker","volume":"343","author":"Solca","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109162_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.xinn.2021.100103","article-title":"Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors","volume":"2","author":"Du","year":"2021","journal-title":"The Innovation"},{"issue":"3","key":"10.1016\/j.bioorg.2025.109162_bb0070","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10456-023-09876-7","article-title":"Pathological angiogenesis: mechanisms and therapeutic strategies","volume":"26","author":"Dudley","year":"2023","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bioorg.2025.109162_bb0075","doi-asserted-by":"crossref","unstructured":"D.-p. Wang, K.-l. Liu, X.-y. Li, G.-q. Lu, W.-h. Xue, X.-h. Qian, F.-h. Meng, Design, synthesis, and in vitro and in vivo anti-angiogenesis study of a novel vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor based on 1, 2, 3-triazole scaffold, Eur. J. Med. Chem. 211 (2021) 113083.","DOI":"10.1016\/j.ejmech.2020.113083"},{"key":"10.1016\/j.bioorg.2025.109162_bb0080","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bioorg.2014.05.010","article-title":"Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold","volume":"56","author":"Shahin","year":"2014","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109162_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104350","article-title":"Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors","volume":"104","author":"Saleh","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109162_bb0090","first-page":"1","article-title":"Revisiting VEGF\/VEGFR-2 signaling as an anticancer target and its inhibitor discovery: where are we and where should we go?","author":"Yao","year":"2025","journal-title":"Journal of Drug Targeting (just-accepted)"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109162_bb0095","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2174\/0115734099269413231018065351","article-title":"Discovery of novel pyrimidine based small molecule inhibitors as VEGFR-2 inhibitors: design","volume":"21","author":"Dhawale","year":"2025","journal-title":"Synthesis, and Anti-cancer Studies, Current Computer-Aided Drug Design"},{"key":"10.1016\/j.bioorg.2025.109162_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jfluchem.2023.110163","article-title":"Synthesis, structure, in vitro and in silico enzyme (COX-1\/2 and VEGFR-2) inhibition studies of the 2-arylsulfonamidoacetophenones","volume":"270","author":"Mphahlele","year":"2023","journal-title":"J. Fluor. Chem."},{"key":"10.1016\/j.bioorg.2025.109162_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103224","article-title":"Arylpropionic acid-derived NSAIDs: new insights on derivatization, anticancer activity and potential mechanism of action","volume":"92","author":"Gouda","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109162_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112439","article-title":"Expanding the anticancer potential of 1, 2, 3-triazoles via simultaneously targeting Cyclooxygenase-2, 15-lipoxygenase and tumor-associated carbonic anhydrases","volume":"200","author":"Elzahhar","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.109162_bb0115","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/94.4.252","article-title":"Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues","volume":"94","author":"Thun","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"32","key":"10.1016\/j.bioorg.2025.109162_bb0120","doi-asserted-by":"crossref","first-page":"33290","DOI":"10.18632\/oncotarget.5396","article-title":"Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma","volume":"6","author":"Rao","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.109162_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112996","article-title":"Synthesis and evaluation of new quinazoline-benzimidazole hybrids as potent anti-microbial agents against multidrug resistant Staphylococcus aureus and mycobacterium tuberculosis","volume":"212","author":"Malasala","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109162_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115831","article-title":"Design, synthesis, and structure-activity relationships of a novel class of quinazoline derivatives as coronavirus inhibitors","volume":"261","author":"Zhou","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109162_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116137","article-title":"5+ 1-Heterocyclization as preparative approach for carboxy-containing triazolo [1, 5-c] quinazolines with anti-inflammatory activity","volume":"266","author":"Krasovska","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109162_bb0140","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3390\/molecules25061467","article-title":"Microwave assisted synthesis of 4-Phenylquinazolin-2 (1H)-one derivatives that inhibit vasopressor tonus in rat thoracic aorta","volume":"25","author":"Teixeira","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109162_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112333","article-title":"Antioxidant activity of novel quinazolinones bearing sulfonamide: potential radiomodulatory effects on liver tissues via NF-\u03baB\/PON1 pathway","volume":"197","author":"Soliman","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109162_bb0150","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/scipharm91020018","article-title":"Medicinal chemistry of quinazolines as anticancer agents targeting tyrosine kinases","volume":"91","author":"Zayed","year":"2023","journal-title":"Sci. Pharm."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109162_bb0155","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1039\/C7MD00097A","article-title":"An insight into the therapeutic potential of quinazoline derivatives as anticancer agents","volume":"8","author":"Ahmad","year":"2017","journal-title":"MedChemComm"},{"issue":"1","key":"10.1016\/j.bioorg.2025.109162_bb0160","first-page":"43","article-title":"A review of Quinazoline-based EGFR\/VEGFR-2 dual inhibitors as potent anticancer agents: structure-activity relationship and docking studies","volume":"31","author":"Yousefbeyk","year":"2025","journal-title":"Pharmaceutical Sciences"},{"key":"10.1016\/j.bioorg.2025.109162_bb0165","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.ejmech.2016.11.030","article-title":"Green synthesis and anticancer potential of chalcone linked-1, 2, 3-triazoles","volume":"126","author":"Yadav","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109162_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130042","article-title":"Synthesis, characterization, and antioxidant and anticancer activity of 1, 4-disubstituted 1, 2, 3-triazoles","volume":"1232","author":"\u015eahin","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.109162_bb0175","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.661173","article-title":"1, 2, 3-Triazole-containing compounds as anti\u2013lung cancer agents: current developments, mechanisms of action, and structure\u2013activity relationship","volume":"12","author":"Liang","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109162_bb0180","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1517\/17460441.2016.1135125","article-title":"An overview of molecular hybrids in drug discovery","volume":"11","author":"B\u00e9rub\u00e9","year":"2016","journal-title":"Expert Opin. Drug Discovery"},{"issue":"2","key":"10.1016\/j.bioorg.2025.109162_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e13528","article-title":"Design, synthesis, and cytotoxic evaluation of quinazoline derivatives bearing triazole-acetamides","volume":"9","author":"Pedrood","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.bioorg.2025.109162_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103987","article-title":"Synthetic approaches, anticancer potential, HSP90 inhibition, multitarget evaluation, molecular modeling and apoptosis mechanistic study of thioquinazolinone skeleton: promising antibreast cancer agent","volume":"101","author":"El-Shafey","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109162_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107437","article-title":"Novel quinazolin-2-yl 1, 2, 3-triazole hybrids as promising multi-target anticancer agents: design, synthesis, and molecular docking study","volume":"148","author":"El Hamaky","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109162_bb0200","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ejmech.2017.12.065","article-title":"Novel click modifiable thioquinazolinones as anti-inflammatory agents: design, synthesis, biological evaluation and docking study","volume":"144","author":"Moussa","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109162_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107951","article-title":"Harnessing potential COX-2 engagement for boosting anticancer activity of substituted 2-mercapto-4(3H)-quinazolinones with promising EGFR\/VEGFR-2 inhibitory activities","volume":"153","author":"Hamdi","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109162_bb0210","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.2147\/DDDT.S490930","article-title":"Design, synthesis, pharmacological evaluation of Quinazolin-4 (3H)-ones bearing urea functionality as potential VEGFR-2 inhibitors","author":"Al-Sanea","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"issue":"14","key":"10.1016\/j.bioorg.2025.109162_bb0215","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.4155\/fmc.12.121","article-title":"Development and strategies of VEGFR-2\/KDR inhibitors","volume":"4","author":"Huang","year":"2012","journal-title":"Future Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109162_bb0220","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1021\/jm901443h","article-title":"Through the \u201cgatekeeper door\u201d: exploiting the active kinase conformation","volume":"53","author":"Zuccotto","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109162_bb0225","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejmech.2013.11.023","article-title":"A development of chimeric VEGFR2 TK inhibitor based on two ligand conformers from PDB: 1Y6A complex \u2013 medicinal chemistry consequences of a TKs analysis","volume":"72","author":"Lintnerov\u00e1","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"18","key":"10.1016\/j.bioorg.2025.109162_bb0230","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1016\/S0960-894X(03)00656-5","article-title":"The kinetics of binding to p38MAP kinase by analogues of BIRB 796","volume":"13","author":"Regan","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109162_bb0235","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2017.04.068","article-title":"Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors","volume":"136","author":"Abdullaziz","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109162_bb0240","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jmgm.2008.11.008","article-title":"Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2","volume":"27","author":"Xie","year":"2009","journal-title":"J. Mol. Graph. Model."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109162_bb0245","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ygyno.2013.11.029","article-title":"Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma\u2014Mechanistics, review of phase III randomized clinical trials, and regulatory implications","volume":"132","author":"Eskander","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109162_bb0250","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1016\/j.ejmech.2010.09.002","article-title":"Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors","volume":"45","author":"Lee","year":"2010","journal-title":"Eur. J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2025.109162_bb0255","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1016\/j.bmc.2015.08.010","article-title":"Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno [3, 2-b] pyridin-7-ylthio) phenyl] ureas: discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors","volume":"23","author":"Machado","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.109162_bb0260","article-title":"Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF\/VEGFR-2 signaling pathway","volume":"8","author":"Wang","year":"2013","journal-title":"PloS One"},{"issue":"54","key":"10.1016\/j.bioorg.2025.109162_bb0265","doi-asserted-by":"crossref","first-page":"39977","DOI":"10.1039\/D4RA07367C","article-title":"Rational design and synthesis of novel phenyltriazole derivatives targeting MRSA cell wall biosynthesis","volume":"14","author":"Elsebaei","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109162_bb0270","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s10593-014-1559-3","article-title":"Synthesis of 4-(1 \u041d-1, 2, 3-Triazol-4-Yl)-1, 3-Thiazole-2-amine derivatives","volume":"50","author":"Bunev","year":"2014","journal-title":"Chem. Heterocycl. Compd."},{"issue":"1\u20132","key":"10.1016\/j.bioorg.2025.109162_bb0275","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2025.109162_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108377","article-title":"New pyrrolo [3, 4-d] isoxazolidines hybrid with furan as antitumor agents and multi-target enzyme inhibitors: synthesis and in silico study","volume":"159","author":"Said","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2025.109162_bb0285","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jsps.2019.04.003","article-title":"Synthesis, anticancer, apoptosis-inducing activities and EGFR and VEGFR2 assay mechanistic studies of 5,5-diphenylimidazolidine-2,4-dione derivatives: molecular docking studies","volume":"27","author":"Alkahtani","year":"2019","journal-title":"Saudi Pharm J"},{"issue":"36","key":"10.1016\/j.bioorg.2025.109162_bb0290","doi-asserted-by":"crossref","first-page":"26325","DOI":"10.1039\/D4RA04828H","article-title":"S-alkylated quinazolin-4 (3 H)-ones as dual EGFR\/VEGFR-2 kinases inhibitors: design, synthesis, anticancer evaluation and docking study","volume":"14","author":"Tawfik","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109162_bb0295","first-page":"587","article-title":"New series of VEGFR-2 inhibitors and apoptosis enhancers: design, synthesis and biological evaluation","author":"Abdallah","year":"2023","journal-title":"Drug Des. Devel. Ther."},{"issue":"16","key":"10.1016\/j.bioorg.2025.109162_bb0300","doi-asserted-by":"crossref","first-page":"9442","DOI":"10.3390\/ijms23169442","article-title":"Augmented therapeutic potential of ec-synthetic retinoids in caco-2 cancer cells using an in vitro approach","volume":"23","author":"Abdelaal","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bioorg.2025.109162_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsps.2023.101803","article-title":"Synthesis of novel spirochromane incorporating Schiff's bases, potential antiproliferative activity, and dual EGFR\/HER2 inhibition: cell cycle analysis and in silico study","volume":"31","author":"Othman","year":"2023","journal-title":"Saudi Pharmaceutical Journal"},{"key":"10.1016\/j.bioorg.2025.109162_bb0310","article-title":"Design and synthesis of novel 2-S-alkylated Quinazolinones as dual BRAFV600E and EGFR inhibitors in melanoma: mechanistic insights from apoptosis and cell cycle modulation","volume":"108526","author":"El-Shafey","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109162_bb0315","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/abio.2000.4690","article-title":"Quantification of active caspase 3 in apoptotic cells","volume":"284","author":"Saunders","year":"2000","journal-title":"Anal. Biochem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.109162_bb0320","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1006\/nbdi.2002.0549","article-title":"Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain","volume":"11","author":"Rohn","year":"2002","journal-title":"Neurobiol. Dis."},{"issue":"45","key":"10.1016\/j.bioorg.2025.109162_bb0325","doi-asserted-by":"crossref","first-page":"11225","DOI":"10.1021\/ja9621760","article-title":"Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids","volume":"118","author":"Jorgensen","year":"1996","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.bioorg.2025.109162_bb0330","doi-asserted-by":"crossref","first-page":"13806","DOI":"10.33263\/BRIAC116.1380613828","article-title":"Computer-based approaches for determining the pharmacological profile of 5-(3-nitro-arylidene)-thiazolidine-2, 4-dione","volume":"11","author":"Sakib","year":"2021","journal-title":"Biointerface Research in Applied Chemistry"},{"key":"10.1016\/j.bioorg.2025.109162_bb0335","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejmech.2017.04.057","article-title":"Structural characterization of Giardia duodenalis thioredoxin reductase (gTrxR) and computational analysis of its interaction with NBDHEX","volume":"135","author":"Brogi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.109162_bb0340","doi-asserted-by":"crossref","first-page":"2162511","DOI":"10.1080\/14756366.2022.2162511","article-title":"Design, synthesis, and biological investigation of oxadiazolyl, thiadiazolyl, and pyrimidinyl linked antipyrine derivatives as potential non-acidic anti-inflammatory agents","volume":"38","author":"Al-Sanea","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109162_bb0345","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ejmech.2018.03.024","volume":"150","author":"Vallone","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109162_bb0350","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3389\/fchem.2019.00574","article-title":"Identification of novel 3-hydroxy-pyran-4-one derivatives as potent HIV-1 integrase inhibitors using in silico structure-based combinatorial library design approach","volume":"7","author":"Sirous","year":"2019","journal-title":"Front. Chem."},{"issue":"27","key":"10.1016\/j.bioorg.2025.109162_bb0355","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.1021\/j100078a035","article-title":"A multiple-time-step molecular dynamics algorithm for macromolecules","volume":"98","author":"Humphreys","year":"1994","journal-title":"J. Phys. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2025.109162_bb0360","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1103\/PhysRevA.31.1695","article-title":"Canonical dynamics: equilibrium phase-space distributions","volume":"31","author":"Hoover","year":"1985","journal-title":"Phys. Rev. A"},{"issue":"4177","key":"10.1016\/j.bioorg.2025.109162_bb0365","first-page":"10.1063","article-title":"Constant pressure molecular dynamics algorithms","volume":"101","author":"Martyna","year":"1994","journal-title":"J. Chem. Phys."},{"issue":"19","key":"10.1016\/j.bioorg.2025.109162_bb0370","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1063\/1.470117","article-title":"A smooth particle mesh Ewald method","volume":"103","author":"Essmann","year":"1995","journal-title":"J. Chem. Phys."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825010429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825010429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:09:23Z","timestamp":1766102963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825010429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":74,"alternative-id":["S0045206825010429"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109162","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting COX-2 engagement for amplifying anticancer potential of Quinazoline-triazole conjugates with superior EGFR\/VEGFR-2 inhibition","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109162"}}